Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer
The 5-year results from the CROWN study showed that more people who took lorlatinib continued to benefit from their treatment than those who took crizotinib. The 5-year benefit of lorlatinib in people with <i>ALK</i>-positive NSCLC has never been seen before.<b>Clinical Trial Registration:</b> NCT03052608 (Phase 3 CROWN study) (ClinicalTrials.gov).
Authors
- Jean-François Martini (ORCID: https://orcid.org/0000-0001-8570-1401)
- Filippo de Marinis (ORCID: https://orcid.org/0000-0002-1118-5536)
- Francesca Toffalorio
- Ross A. Soo (ORCID: https://orcid.org/0000-0002-3053-3997)
- Yasushi Goto (ORCID: https://orcid.org/0000-0002-7437-5054)
- Jolanda Paolini (ORCID: https://orcid.org/0000-0003-2711-5302)
- Todd M. Bauer (ORCID: https://orcid.org/0000-0002-3078-5043)
- Benjamin Solomon (ORCID: https://orcid.org/0000-0003-3059-5730)
- Julien Mazières (ORCID: https://orcid.org/0000-0002-5921-7613)
- Tony Mok (ORCID: https://orcid.org/0000-0002-8251-0551)
- Rossella Messina
- Despina Thomaidou (ORCID: https://orcid.org/0000-0003-3788-4623)
- Alice T. Shaw (ORCID: https://orcid.org/0000-0001-6337-1093)
- Anna Polli
- Enriqueta Felip (ORCID: https://orcid.org/0000-0002-7620-0098)
- Yi-Long Lung Cancer Wu (ORCID: https://orcid.org/0000-0002-3611-0258)
- Dong‐Wan Kim (ORCID: https://orcid.org/0000-0001-5124-7132)
- Geoffrey Liu (ORCID: https://orcid.org/0000-0002-2603-7296)
Institutions
- Hebron University (PS)
- Chinese University of Hong Kong (HK)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Pfizer (United States) (US)
- Peter MacCallum Cancer Centre (AU)
- Cancer Institute (WIA) (IN)
- Princess Margaret Cancer Centre (CA)
- Seoul National University Hospital (KR)
- Massachusetts General Hospital (US)
- National Cancer Center (US)
- National University Cancer Institute, Singapore (SG)
- The Centers (US)
- Vall d'Hebron Hospital Universitari (ES)
- Tennessee Oncology (US)
- Pfizer (Italy) (IT)
- Guangdong Academy of Medical Sciences (CN)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Guangdong Provincial People's Hospital (CN)
- State Key Laboratory of Chemical Engineering (CN)
- Vall d'Hebron Institute of Oncology (ES)
- European Institute of Oncology (IT)
- South China University of Technology (CN)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1080/14796694.2024.2406117
- Citations
- 1
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- BeiGene
- Genentech